When antidepressants do not work, many patients conclude that their depression is untreatable.
That conclusion is understandable, but it is often premature.
Treatment-resistant depression does not mean there are no remaining options. It usually means that standard first-line treatments have not provided enough relief, and the next step requires a more careful treatment plan.
At Dignity Brain Health, treatment-resistant depression care may include psychiatric medication management, review of prior medication trials, and TMS therapy for eligible adults with depression at our Brookline, Massachusetts office near Boston.
Quick Answer: What Is Treatment-Resistant Depression?
Treatment-resistant depression usually refers to major depressive disorder that has not improved enough after multiple adequate antidepressant treatment trials. Definitions vary, but many clinical frameworks define treatment resistance as inadequate response to at least two adequate antidepressant trials (Voineskos et al., 2020).
If antidepressants have not helped enough, treatment options may include medication optimization, switching medications, augmentation strategies, psychotherapy, TMS therapy, ECT, ketamine/esketamine treatment, or other approaches depending on the patient’s clinical history and safety needs.
At Dignity Brain Health, TMS therapy is provided in person in Brookline, MA, near Boston, for eligible adults with depression. Psychiatric medication management may also be available in person near Boston and by telehealth when clinically appropriate.
What Treatment-Resistant Depression Means
Treatment-resistant depression is not a separate personality type, a weakness, or a sign that someone is beyond help.
It is a clinical pattern: depression has not improved enough after one or more appropriate treatments.
The term is used because some people with major depressive disorder do not respond adequately to initial antidepressant treatment. In the STAR*D trial, many patients did not reach remission after the first antidepressant step, and remission became less likely after multiple failed treatment steps (Rush et al., 2006).
This is one reason careful follow-up matters. If treatment is not working, the next step should not simply be “try another medication indefinitely.” The treatment history should be reviewed, the diagnosis should be reassessed, and other options should be considered.
Why Antidepressants Do Not Work for Everyone
Antidepressants can be effective for many people with major depressive disorder, but response varies.
A medication may not work well because of:
- Incomplete response to the medication’s mechanism
- Side effects that prevent adequate dosing
- Inadequate dose or duration
- Co-occurring anxiety, PTSD, ADHD, insomnia, substance use, or medical illness
- Bipolar-spectrum illness that has not been recognized
- Medication interactions
- Adherence challenges
- Chronic stress or psychosocial factors
- Genetic or metabolic differences
- Depression severity or chronicity
Before labeling depression as treatment-resistant, it is important to review whether prior medication trials were adequate in dose and duration and whether the diagnosis and clinical context have been fully assessed.
When Antidepressants “Stop Working”
Some patients feel better initially and then relapse. Others never respond meaningfully. Some improve partially but remain impaired.
When antidepressants stop working or never worked well enough, the next step may involve:
- Reassessing the diagnosis
- Reviewing medication history carefully
- Checking whether past trials were adequate
- Addressing sleep, anxiety, trauma, ADHD, or medical contributors
- Considering medication adjustment or augmentation
- Considering psychotherapy or a different therapy approach
- Considering TMS therapy for depression
- Considering higher-level or specialty treatments when clinically indicated
The right next step depends on the patient’s history, symptoms, safety, prior response, and goals.
Treatment Options After Multiple Antidepressants
Treatment-resistant depression is best approached with a structured plan.
Options may include:
Medication Optimization
Sometimes a previous medication trial was too short, too low in dose, or stopped because of side effects that could have been managed differently. In other cases, a medication may need to be changed or augmented.
Psychiatric medication management can help review what has been tried and determine whether additional medication strategies are appropriate.
[Learn About Psychiatric Medication Management]
Psychotherapy
Therapy can be important when depression is connected to grief, trauma, avoidance, relationship stress, self-criticism, anxiety, or patterns that medication alone does not address.
Medication and therapy can be complementary.
TMS Therapy
TMS, or transcranial magnetic stimulation, is a noninvasive treatment that uses magnetic pulses to stimulate targeted areas of the brain involved in mood regulation.
TMS has evidence for major depressive disorder, including patients who have not benefited adequately from antidepressant medication. A multisite randomized controlled trial found that TMS was effective for acute treatment of major depression and was generally well tolerated (O’Reardon et al., 2007). Clinical TMS Society consensus recommendations also support daily left prefrontal TMS as an evidence-based treatment option for treatment-resistant or medication-intolerant depression (Perera et al., 2016).
ECT, Ketamine, Esketamine, or Other Specialty Treatments
Some patients with severe, psychotic, highly suicidal, catatonic, or otherwise complex depression may need treatments such as ECT, ketamine/esketamine, intensive outpatient care, partial hospitalization, inpatient care, or another specialty intervention.
Dignity Brain Health does not present TMS as the only option for treatment-resistant depression. A careful evaluation should determine which option is clinically appropriate.
TMS Therapy for Treatment-Resistant Depression Near Boston
Dignity Brain Health provides TMS therapy in person at:
1101 Beacon Street, Suite 8W
Brookline, MA 02446
Our Brookline office is near Boston and serves patients from Brookline, Boston, Cambridge, Newton, Somerville, Quincy, Framingham, Watertown, Waltham, Needham, Brighton, Allston, Fenway, Back Bay, Jamaica Plain, and surrounding Massachusetts communities.
TMS is not available by telehealth. Patients must be able to attend repeated in-person treatment sessions at the Brookline office.
What a TMS Course Involves
TMS therapy is delivered as a course of repeated sessions over several weeks.
At Dignity Brain Health, a common TMS course involves approximately 36 sessions over about 7 weeks, depending on the protocol, insurance authorization, clinical response, and treatment plan.
TMS sessions do not require anesthesia or sedation. Most patients can drive themselves to and from treatment and return to normal activities afterward.
Because TMS is cumulative, consistency matters. The treatment schedule should be discussed before starting.
What the Research Shows About TMS Outcomes
TMS has been studied in randomized trials and real-world clinical practice.
In a multisite randomized controlled trial, O’Reardon et al. (2007) found that TMS was effective and generally well tolerated for acute treatment of major depression.
In a large naturalistic observational study, Carpenter et al. (2012) found that TMS was associated with clinically meaningful outcomes in real-world practice among patients with major depression who had not benefited from antidepressant medication.
A later large registry study by Sackeim et al. (2020) also reported clinically meaningful outcomes among patients with major depressive disorder treated with TMS in routine practice.
These findings support TMS as a treatment option for some patients with depression, but they do not guarantee an individual result. Response depends on diagnosis, treatment history, symptom severity, co-occurring conditions, attendance consistency, and individual biology.
Is TMS Right for Everyone With Treatment-Resistant Depression?
No.
TMS may be appropriate for some adults with major depressive disorder or treatment-resistant depression, but not every patient is a candidate.
Candidacy depends on:
- Diagnosis
- Prior antidepressant trials
- Symptom severity
- Medical history
- Psychiatric history
- Seizure risk
- Implanted devices or metal considerations
- Insurance requirements
- Ability to attend repeated in-person sessions
- Safety and clinical appropriateness
Patients with certain histories may need a different treatment approach. The evaluation is designed to clarify this before treatment begins.
Medication Management Still Matters
TMS is not a replacement for all psychiatric care.
Many patients continue medication management before, during, or after TMS. Medication management may involve reviewing current medications, adjusting treatment, monitoring symptoms, managing side effects, or planning next steps after a TMS course.
For patients with treatment-resistant depression, the goal is not simply to try the next medication on a list. The goal is to understand what has been tried, what helped, what failed, what caused side effects, and what the current clinical picture suggests.
What About Genetic Testing?
Some patients with treatment-resistant depression ask whether genetic testing can help.
Pharmacogenomic testing may provide information about how the body metabolizes certain psychiatric medications. It does not diagnose depression and does not guarantee which medication will work.
For selected patients with multiple medication trials, unusual side effects, or complex medication histories, pharmacogenomic information may be one useful data point. It should be interpreted by a clinician in the context of the full history.
Insurance Coverage for TMS in Massachusetts
TMS therapy for depression is covered by many major Massachusetts insurance plans when medical-necessity and prior authorization requirements are met.
Coverage depends on diagnosis, prior treatment history, plan criteria, documentation, deductible, copay, coinsurance, and authorization requirements.
Medicare and MassHealth may be accepted for TMS therapy when coverage requirements are met. Medicare, Medicaid, and MassHealth are not accepted for psychiatric medication management, online psychiatry, or therapy at Dignity Brain Health.
Dignity Brain Health reviews insurance information before treatment begins and helps determine whether prior authorization is required.
When to Seek Urgent Help
Treatment-resistant depression can be serious.
If you are in immediate danger, may harm yourself, or feel unable to stay safe, call 911, call or text 988, or go to the nearest emergency department.
Dignity Brain Health’s online intake is not monitored for emergencies.
Frequently Asked Questions
What is treatment-resistant depression?
Treatment-resistant depression generally refers to depression that has not improved enough after multiple adequate treatment trials. Many clinical frameworks use inadequate response to at least two antidepressant trials as a common threshold, though definitions vary.
Does treatment-resistant depression mean nothing will work?
No. It means prior treatments have not worked well enough. Other options may still be appropriate, including medication optimization, therapy, TMS therapy, ECT, ketamine/esketamine treatment, or another level of care depending on the situation.
How many antidepressants do I need to try before TMS?
Requirements vary by clinical situation and insurance plan. At Dignity Brain Health, TMS candidacy depends on diagnosis, prior antidepressant trials, safety considerations, and insurance requirements. The evaluation helps clarify whether TMS is an appropriate next step.
Can I do TMS while still taking antidepressants?
Many patients continue medication during TMS. Whether to continue, adjust, taper, or change medication is a clinical decision made with your prescriber.
Is TMS available by telehealth?
No. TMS is provided in person at Dignity Brain Health’s Brookline office near Boston.
How many TMS sessions are typical?
At Dignity Brain Health, a common TMS course involves approximately 36 sessions over about 7 weeks, depending on protocol, insurance authorization, clinical response, and treatment plan.
Does TMS require anesthesia?
No. TMS does not require anesthesia or sedation.
Can I drive after TMS?
Most patients can drive themselves to and from TMS treatment and return to normal activities afterward.
What happens if TMS does not help enough?
If TMS does not provide enough improvement, next steps may include medication management, therapy, reassessment of diagnosis, treatment of co-occurring conditions, referral for another treatment, or another level of care.
Is treatment-resistant depression covered by insurance?
Insurance coverage depends on the service. TMS therapy for depression is covered by many Massachusetts insurance plans when medical-necessity and prior authorization requirements are met.
Does Dignity Brain Health accept Medicare or MassHealth for treatment-resistant depression?
Medicare and MassHealth may be accepted for TMS therapy when coverage requirements are met. Medicare, Medicaid, and MassHealth are not accepted for psychiatric medication management, online psychiatry, or therapy.
Where can I get treatment-resistant depression care near Boston?
Dignity Brain Health offers TMS therapy for depression in Brookline, MA, near Boston, and psychiatric medication management when clinically appropriate.
How do I start the process?
The first step is to complete Dignity Brain Health’s secure intake. The team will review your symptoms, treatment history, insurance, safety considerations, and clinical needs before guiding you toward the appropriate next step.
Key Takeaways
- Treatment-resistant depression means prior treatment has not worked well enough; it does not mean depression is untreatable.
- Many definitions use inadequate response to at least two adequate antidepressant trials, though definitions vary.
- Options may include medication optimization, therapy, TMS therapy, ECT, ketamine/esketamine treatment, or another level of care depending on clinical need.
- Dignity Brain Health provides TMS therapy for depression in Brookline, MA, near Boston.
- A common TMS course involves approximately 36 sessions over about 7 weeks.
- TMS response varies by patient and is not guaranteed.
- Medicare and MassHealth may be accepted for TMS therapy when coverage requirements are met.
- Psychiatric medication management may remain important before, during, or after TMS.
Start Treatment-Resistant Depression Care Near Boston
If antidepressants have not helped enough, your history deserves a careful review.
Dignity Brain Health provides TMS therapy for depression at our Brookline office near Boston and psychiatric medication management when clinically appropriate. The first step is to complete our secure intake so the team can review your symptoms, treatment history, insurance, safety considerations, and clinical needs.
References
Carpenter, L. L., Janicak, P. G., Aaronson, S. T., Boyadjis, T., Brock, D. G., Cook, I. A., Dunner, D. L., Lanocha, K., Solvason, H. B., & Demitrack, M. A. (2012). Transcranial magnetic stimulation (TMS) for major depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 29(7), 587–596. https://doi.org/10.1002/da.21969
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., Demitrack, M. A., George, M. S., & Sackeim, H. A. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biological Psychiatry, 62(11), 1208–1216. https://doi.org/10.1016/j.biopsych.2007.01.018
Perera, T., George, M. S., Grammer, G., Janicak, P. G., Pascual-Leone, A., & Wirecki, T. S. (2016). The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimulation, 9(3), 336–346. https://doi.org/10.1016/j.brs.2016.03.010
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Sackeim, H. A., Aaronson, S. T., Carpenter, L. L., Hutton, T. M., Mina, M., Pages, K., Verdoliva, S., West, W. S., & Dunner, D. L. (2020). Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation. Journal of Affective Disorders, 277, 65–74. https://doi.org/10.1016/j.jad.2020.08.005
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020). Management of treatment-resistant depression: Challenges and strategies. Neuropsychiatric Disease and Treatment, 16, 221–234. https://doi.org/10.2147/NDT.S198774
Mayo Clinic. Symptoms of Depression. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
Mayo Clinic. Transcranial Magnetic Stimulation. https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625
National Institutes of Health. TMS FDA Approval and Clinical Evidence. https://pmc.ncbi.nlm.nih.gov/articles/PMC8864803/
Medical Disclaimer
This article is for educational purposes only and is not medical advice, diagnosis, treatment, or a guarantee of results. Treatment-resistant depression should be evaluated by a licensed clinician who has reviewed the patient’s full medical and psychiatric history. TMS therapy, medication management, ECT, ketamine/esketamine treatment, and other treatments have different risks, benefits, eligibility criteria, and insurance requirements. If you are in immediate danger or may harm yourself, call 911, call or text 988, or go to the nearest emergency department.